Cytosorbents Corporation: updates and filings

CTSONASDAQHealthcare · Surgical & Medical Instruments & Apparatus

Price

$4.37

November 18, 2026

What Ploutos Investor adds for Cytosorbents

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 15 fiscal years, from 2011
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 43% since Aug 6, 2026, when the 10-Q these figures come from was filed ($7.98 then, $4.52 on Nov 17, 2026). The figures date from before that move.10-Q
  • The share price was recently adjusted for a split or a spin-off that the company's last filing does not include yet. Market value, P/E, yields and the other figures measured against the price would mix the new shares with the old figures, so we leave them out until the next filing.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 30, 2026 latest annualAug 6, 2026 latest quarterly
  • Nov 17, 2026Notice that the quarterly report will be filed late
    FormNT 10-Q
  • Nov 12, 2026Results of operations
    Form8-K
  • Sep 23, 2026Regulation FD disclosure, other material events
    Form8-K
  • Sep 8, 2026Amended articles or bylaws
    Form8-K
  • Aug 14, 2026Shareholder vote
    Form8-K
  • Aug 7, 2026Regulation FD disclosure
    Form8-K
  • Aug 6, 2026Results of operations
    Form8-K
  • Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Jul 6, 2026Delisting notice
    Form8-K
  • Jun 25, 2026Annual report to shareholdersfor the period to Dec 31, 2025
    FormARS
  • Jun 25, 2026Additional annual meeting material
    FormDEFA14A
  • Jun 25, 2026Annual meeting proxy statement
    FormDEF 14A
  • Jun 25, 2026Regulation FD disclosure
    Form8-K
  • Jun 11, 2026Preliminary proxy statement
    FormPRE 14A
  • May 13, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 13, 2026Results of operations
    Form8-K
  • Apr 15, 2026Annual report (amendment)for the period to Dec 31, 2025
    Form10-K/A
  • Apr 2, 2026Delisting notice
    Form8-K
  • Mar 30, 2026Annual reportfor the period to Dec 31, 2025
    Form10-K
  • Mar 25, 2026Results of operations, Regulation FD disclosure
    Form8-K
  • Feb 13, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 13, 2025Results of operations
    Form8-K
  • Nov 13, 2025Quarterly reportfor the period to Sep 30, 2025
    Form10-Q
  • Oct 3, 2025Delisting notice
    Form8-K
  • Sep 16, 2025Regulation FD disclosure, other material events
    Form8-K

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Mar 29, 2004.

The full analysis

What do Cytosorbents's filings show?

The filings are where every one of Cytosorbents's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.